Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients

The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.

Inclusion Criteria:

•Subjects who have completed the 24-week C2L-OCT-01 PR-301 study

Exclusion Criteria:

• Women of childbearing potential who are not taking adequate contraception or who are pregnant or lactating
• Subjects who have experienced any clinically significant adverse event related to study medication in C2L-OCT-01 PR-301 study
• Subjects with uncontrolled Diabetes type II
• Subjects with signs or symptoms related to a tumor compression of the optical chiasm
• Subjects with symptomatic cholelithiasis